Seattle, WA, United States
Seattle, WA, United States

Time filter

Source Type

Dubensky T.W.,Immune Design | Reed S.G.,Immune Design
Seminars in Immunology | Year: 2010

The recent FDA approval of sipuleucel-T (Provenge®), a patient-specific immunotherapy for androgen-independent prostate cancer developed by Dendreon Corporation, has provided support for the concept of cellular immunotherapy as an approach to cancer treatment. Adjuvants are compounds that enhance the potency of the antigen-specific immune response and can be an essential component of an efficacious vaccine. Cervarix is a prophylactic vaccine against human papilloma virus (HPV) types 16 and 18, which can cause cervical cancer, and recently received approval from the FDA, due in part to the protective immunity it conferred against not only HPV types contained in the vaccine but in addition to oncogenic HPV strains that were not contained in the vaccine. Cervarix® is formulated with MPL (monophosphoryl lipid A), a TLR-4 targeted adjuvant shown to promote immune response broadening. The recent FDA approvals of these pioneering vaccines are landmark events, and will likely usher in renewed interest and investment in the development of new therapeutic cancer vaccine candidates. In this review, we examine new molecularly defined adjuvants and formulations and its application to cancer vaccines under development. © 2010 Elsevier Ltd.


Lentiviral vector particles comprising a Sindbis virus E2 glycoprotein variant and a lentiviral vector genome comprising a sequence of interest are provided. A lentiviral vector particle comprising: (a) an envelope comprising a Sindbis virus E2 glycoprotein variant; and (b) a lentiviral vector genome comprising a sequence of Interest; wherein the E2 glycoprotein variant facilitates infection of dendritic cells by the lentiviral vector particle, and wherein the E2 glycoprotein variant has reduced binding to heparan sulfate compared to a reference sequence (HR strain).


Patent
Immune Design | Date: 2014-04-18

The present disclosure relates generally to compositions and methods for treating cancer with a glucopyranosyl lipid A (GLA) in the absence of antigen.


Patent
Immune Design | Date: 2015-01-20

Compositions and methods are provided herein for treatment of allergic conditions, by administration of an adjuvant composition, with or without allergen.


Patent
Immune Design | Date: 2014-07-17

The present disclosure relates generally to compositions and methods for treating cancer with a glucopyranosyl lipid A (GLA) in the absence of antigen.


Patent
Immune Design | Date: 2015-01-08

The present disclosure relates generally to compositions and methods for treating cancer with a glucopyranosyl lipid A (GLA) in the absence of antigen.


Compositions and methods are provided herein for improved dual immunization strategies that induce in a subject an immune response that includes a humoral immune response and cellular immune response, both CD4 and CD8 T lymphocyte immune responses, thereby providing a complete adaptive immune response to one or more antigens. The methods described are therefore useful for treating and/or preventing (i.e., reducing the likelihood or risk of occurrence) different diseases, disorders, and conditions such as cancers and infectious diseases for which induction of both a humoral immune response and cellular immune response is desired and beneficial.


Provided herein are compositions and methods for immunotherapy of cancers, said methods combining systemic vaccination with a recombinant expression vector encoding a viral antigen and/or a cancer specific tumor antigen(s) to induce activated CD8 T-cells, with a local (e.g., intratumoral) immune stimulation using standard or modified application of a TLR agonist, to induce local inflammatory and innate immune responses which recruit T-cells to the tumor.


Patent
Immune Design | Date: 2014-09-04

The present invention relates generally to vaccines for drug addiction. In particular, the present disclosure provides adjuvants for significantly improving immune responses generated against addictive drug haptens.


Patent
Immune Design | Date: 2015-08-26

The present disclosure relates generally to compositions and methods for treating cancer with a glucopyranosyl lipid A (GLA) in the absence of antigen.

Loading Immune Design collaborators
Loading Immune Design collaborators